drug · gene
CTx-001
Phase 2updated 5mo agoby Complement Therapeutics Ltd🔗 ChEMBL
Phase 2community read0 votes
Gene drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
indications
indications
AMD
targets
B-cell lymphoma/leukemia 11A
all catalysts(0)
nothing on the calendar yet
Trials studying CTx-001
News(8)
- Novo, BioMarin, Enanta dole out pink slipsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Biotech startup funding gap widens despite rebound in VC investmentThough funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.biopharma_dive · 2mo ago
- Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup🧬 Vertex’s sickle cell gene therapy approved for kids: Casgevy may now be used to treat either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia patie…endpoints · 3mo ago
- FDA Approves First Gene Therapy for Young Children with Sickle Cell DiseaseThe U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recu…fda_press · 3mo ago
- BridgeBio gets funding for drug launch; United buys into cell therapyElsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.biopharma_dive · 3mo ago
- Vertex earnings get muted investor responseWhile overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.biopharma_dive · 4mo ago
- STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and moreIntellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedemastat · 5mo ago
- STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trialWith good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?stat · 5mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that